DURHAM, N.C.--(BUSINESS WIRE)--Biomarck Pharmaceuticals, Ltd., a biopharmaceutical company developing targeted anti-MARCKS technology for the treatment of ARDS [Acute Respiratory Distress Syndrome], cancer and other difficult to treat diseases, today announced new data from a Phase 2 study of its novel anti-MARCKS peptide BIO-11006 in non-small cell lung cancer (NSCLC), will be presented during the American Thoracic Society 2020 (ATS) virtual meeting in August 2020. Kenneth Adler, Ph.D., Professor in the Department of Molecular Biomedical Sciences at North Carolina State University and Chief Scientist of Biomarck Pharmaceuticals will discuss the information during a poster discussion.
“We are pleased to present these compelling results at this year’s ATS conference, which show that inhaled BIO-11006 decreases metastasis and tumor progression, and increases the overall response rate and survival in patients with advanced NSCLC. BIO-11006 appears to have a unique mechanism of action in blocking inflammation and cytokine production in the lungs of patients,” said Professor Adler. “Inflammation and the cytokine storm are well known as a major contributor to ARDS. It is entirely possible that, by blocking inflammation and the cytokine storm in the tumor microenvironment of metastatic lung cancer and of the injured lung in ARDS, BIO-11006 is acting, at least in part, through this similar mechanism of action.”
The full poster entitled, “An Inhaled MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) - Inhibitory Drug, BIO-11006, Elicited a Statistically-Significant Result (p= 0.02) in Overall Response Rate (ORR) After 3 Months Compared to Standard of Care Chemotherapy in a Phase 2 Trial of Late Stage Non-Small Cell Lung Cancer (NSCLC),” discussion session is included in the ATS Journal - here.
BIO-11006 is a novel peptide that inhibits the pro-inflammatory effects of overactive MARCKS protein. The investigational compound was identified and advanced from animal models and human tissue testing into Phase 2 clinical studies based on the research of Dr. Kenneth Adler, Professor in the Department of Molecular Biomedical Sciences at North Carolina State University.
BIO-11006 is being investigated for the treatment of ARDS, Chronic Obstructive Pulmonary Disease (COPD) and Non-Small Cell Lung Cancer (NSCLC). It has a complete pre-clinical package of toxicology and pharmacology data and has been through Phase 1 and 2a trials involving over 300 subjects. BIO-11006 has a well-established safety profile across multiple placebo-controlled studies.
About Biomarck Pharmaceuticals, Ltd.:
Biomarck is a biopharmaceutical company focused on the development of drugs to treat ARDS, COPD, cancer and other hard to treat diseases. With over 100 patented peptides in our global portfolio, we utilize anti-MARCKS proteins to selectively inhibit cancer progression and the inflammatory cytokine release involved in respiratory diseases and other severe illnesses. Learn more about our platform technology and how we are developing safe and targeted treatments for patients in need at www.biomarck.com.
Forward Looking Statements:
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s plans and expectations for BIO-11006, contain predictions, estimates and other forward looking statements. These forward looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risk related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks.
The information in the press release should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.